Trump Fast-Tracks Ibogaine Research With $50 Million as FDA Eyes Psychedelic Approvals
Updated
Updated · CNN · Sep 21
Trump Fast-Tracks Ibogaine Research With $50 Million as FDA Eyes Psychedelic Approvals
3 articles · Updated · CNN · Sep 21
Summary
$50 million in federal support was set aside in Trump’s April executive order to help states study psychedelics, with Ibogaine specifically highlighted as a potential treatment for serious mental illness.
FDA officials said ibogaine could move toward approval once late-stage trial data are reviewed, and the order also pushed priority vouchers meant to speed reviews of psychedelic drugs.
Ibogaine remains a Schedule I substance in the US and carries known risks including dangerous heart-rhythm disturbances, meaning any approval would likely limit use to tightly supervised hospital or clinic settings.
Researchers and advocates called the order a meaningful opening for US-based studies, but said evidence for ibogaine is still modest and $50 million may be too little for large, costly clinical trials.
Interest has grown as veterans and addiction patients seek ibogaine treatment abroad, often in Mexico, underscoring both demand for new mental-health options and the pressure for stronger safety and efficacy data.